InSilico Medicine Cayman TopCo has reached an AI-driven drug development collaboration with Eli Lilly, totaling over 100 million USD
InSilico Medicine Cayman TopCo, a biopharmaceutical technology company driven by generative artificial intelligence, recently reached a strategic cooperation agreement for drug research and development with Eli Lilly, a leading global multinational pharmaceutical company. Both parties will leverage the cutting-edge technological advantages of InSilico Medicine's independently developed AI pharmaceutical platform Pharma.AI, combined with Eli Lilly's deep expertise in drug development and disease research, to jointly accelerate the discovery and development of innovative therapies
Source: Wallstreetcn The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments